Search research articles
Contact Us
Filters
Showing results (81-90 of 277) with videos related to
Page
of 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2021
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma
James M Cleary, Brian M Wolpin, Stephanie K Dougan, et al.
Investigational New Drugs
|
August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
Clinical Pharmacology in Drug Development
|
May 26, 2018
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
Geoffrey I Shapiro, Rebecca S Kristeleit, Howard A Burris, et al.
Cancer Research
|
August 16, 2022
Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers
Jeffrey Patterson-Fortin, Arindam Bose, Wei-Chih Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2013
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors
Geoffrey I Shapiro, Jordi Rodon, Cynthia Bedell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2021
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
Khanh T Do, Bose Kochupurakkal, Sarah Kelland, et al.
Investigational New Drugs
|
November 18, 2016
A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan
James M Cleary, Autumn J McRee, Geoffrey I Shapiro, et al.
Investigational New Drugs
|
June 12, 2014
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
James M Cleary, Caio Max S Rocha Lima, Herbert I Hurwitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2016
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
Jeffrey R Infante, Philippe A Cassier, John F Gerecitano, et al.
Journal of Gastrointestinal Oncology
|
January 24, 2022
Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report
Douglas Rubinson, Brian M Wolpin, Ilana S Warsofsky, et al.
Page
of 28
Search research articles
Search
Showing results (81-90 of 277) with videos related to
Sort By:
Page
of 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2021
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma
James M Cleary, Brian M Wolpin, Stephanie K Dougan, et al.
Investigational New Drugs
|
August 2, 2020
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors
Geoffrey I Shapiro, Patricia LoRusso, Daniel C Cho, et al.
Clinical Pharmacology in Drug Development
|
May 26, 2018
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
Geoffrey I Shapiro, Rebecca S Kristeleit, Howard A Burris, et al.
Cancer Research
|
August 16, 2022
Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers
Jeffrey Patterson-Fortin, Arindam Bose, Wei-Chih Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2013
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors
Geoffrey I Shapiro, Jordi Rodon, Cynthia Bedell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2021
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
Khanh T Do, Bose Kochupurakkal, Sarah Kelland, et al.
Investigational New Drugs
|
November 18, 2016
A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan
James M Cleary, Autumn J McRee, Geoffrey I Shapiro, et al.
Investigational New Drugs
|
June 12, 2014
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
James M Cleary, Caio Max S Rocha Lima, Herbert I Hurwitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2016
A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
Jeffrey R Infante, Philippe A Cassier, John F Gerecitano, et al.
Journal of Gastrointestinal Oncology
|
January 24, 2022
Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report
Douglas Rubinson, Brian M Wolpin, Ilana S Warsofsky, et al.
Page
of 28